Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126425) titled 'A Single-Center, Double-Blind, Randomized Controlled Trial on the Therapeutic Efficacy of NADH in Patients with AIFM1 Mutation-Positive Auditory Neuropathy' on June 9.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Chinese PLA General Hospital
Condition:
Auditory Neuropathy
Intervention:
NADH Group:Oral administration of NADH (40 mg/day) 30 minutes before breakfast each day for 12 weeks.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-06-15
Target Sample Size: NADH Group:25;Placebo Group:25;
Countries of Recruitment:
China
To know more, visit...